#NACFC2021 ֠Trikafta Aids Patients Who Cannot Use Other Modulators

Treatment with Trikafta improves lung function in people with cystic fibrosis (CF) who are not eligible for treatment with other CFTR modulators, according to interim data from an observational study. Results were shared at this yearҳ North American Cystic Fibrosis Conference (NACFC) in the presentation, Ӓeal-world clinical effectiveness of elexacaftor/tezacaftor/ivacaftor and ivacaftor in people with [ŝThe post #NACFC2021 ֠Trikafta Aids Patients Who Cannot Use Other Modulators appeared first on Cystic Fibrosis News Today